Abstract
ABSTRACT This review’s objective is to consolidate knowledge on key endometrial cancer (EC) biomarkers and their molecular underpinnings within the context of the modern era of molecular classification. The review also encompasses an overview of the molecular subtyping of EC, offers recommendations for treatment approaches, and insights into ongoing radiation trials. By integrating clinical and pathologic features to inform treatment decisions, including concurrent chemoradiation, chemotherapy, targeted therapies, endocrine therapy, and immunotherapy, there is potential to enhance EC management and provide patients with more effective and tailored treatment options. Molecular classification offers the foundation for tailor-made treatment strategies, enabling the development of highly precise and personalized plans. This reduces the utilization of unnecessary treatments, offering the prospect of improved outcomes and ultimately elevating the quality of life for patients with EC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call